Aveed (Testosterone Undecanoate) Patent Expiration, LOE Window & CMS Spending
Aveed (Testosterone Undecanoate) by Endo Pharmaceuticals: FDA Orange Book LOE 2027-05-08, 0 AB generics, $3.3M 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Endo Pharmaceuticals |
| FDA Application & Pathway | N022219 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2027-05-08 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $3.3M |
| 2024 Medicare Part D Spend | $1.6M |
| 2024 Medicaid Spend | $1.7M |
| Reported Wholesale Price Change (CA SB 17) | 7 WAC filings (max 33.1% 2-yr change) |